TLR2 Modulation for HSV Infection Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Herpes Simplex Virus (HSV) infections, particularly in neonates, are inadequate in addressing the severe inflammatory cytokine response mediated by Toll-like receptor 2 (TLR2), which contributes to devastating symptoms and high mortality.

Innovation Solution

Identifying and utilizing compounds that inhibit TLR2 expression or activity, such as TLR2 antisense oligonucleotides, small interfering RNA (siRNA), or antibodies, to reduce the inflammatory cytokine response and treat HSV infections by administering them to infected cells or subjects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for HSV infections are used, then viral replication is suppressed, but the inflammatory cytokine response mediated by TLR2 continues to cause severe symptoms and high mortality

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidinflammatory cytokine response severity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent introduces TLR2 as an intermediary target between HSV infection and the harmful inflammatory response. By developing compounds that specifically inhibit TLR2 expression or activity, the treatment intercepts the pathological signaling pathway without directly targeting viral replication, thus reducing the inflammatory cytokine response while managing the infection

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the parameter of TLR2 expression levels or activity state in infected cells. By administering compounds that modulate TLR2 parameters (downregulating expression or inhibiting activity), the harmful inflammatory response is controlled while allowing the immune system to manage viral replication through other pathways

Inventive Principle:

Principle #35Parameter changes

2Productivity

If TLR2-mediated inflammatory response is strongly activated to fight HSV infection, then viral clearance may be enhanced, but severe symptoms and mortality increase

Engineering Contradiction:

Improveviral clearance efficiencyVSAvoidsymptom severity and mortality

Core Design Contradiction:

ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies partial inhibition of TLR2 activity rather than complete suppression. By using compounds that partially modulate TLR2 expression or activity, the treatment allows sufficient immune response for viral clearance while preventing the excessive activation that leads to severe symptoms and mortality

Inventive Principle:

Principle #16Partial or excessive action

Solution Approach 2:

The patent converts the harmful excessive inflammatory response into a beneficial controlled immune reaction. By selectively modulating TLR2, the treatment harnesses the protective aspect of TLR2-mediated immunity for viral clearance while preventing the harmful excessive inflammation that causes severe symptoms

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS8748403B2Modulation of HSV infection

Publication Date: 2014.06.10 UNIV OF MASSACHUSETTS

AI summary

Toll-like receptor 2 (TLR2) has been found to mediate certain effects of HSV infection, particularly in neonates. Compounds that decrease TLR2 expression or activity are useful for ameliorating such deleterious effects.